BIOMAT Database Logo BIOMAT Database Logo

Increased plasma VIP concentration in patients with prolactinoma. 1992

A Makowska, and W Zgliczyński, and J Słowińska-Srzednicka, and P Soszyński, and S Zgliczyński
Department of Endocrinology, Medical Centre for Postgraduate Education, Warsaw.

Vasoactive intestinal polypeptide (VIP) is now considered to be a prolactin-releasing factor (PRF). The aim of this study was to determine the VIP concentration in peripheral blood in patients with prolactin-secreting adenoma compared to healthy subjects. We also examined the effect of bromocriptine administration on the plasma VIP concentration in patients with prolactinoma. Nine patients with prolactinoma (6 women and 3 men, aged 27-50) and 7 healthy control subjects (4 women and 3 men, aged 26-40) were examined. Blood samples for prolactin and VIP were collected at 06:00, 12:00, 18:00, 24:00. In prolactinoma blood was taken before and after bromocriptine administration. Serum prolactin concentration was determined by the radioimmunoassay. VIP concentration was measured by a specific radioimmunoassay Kit-INCSTAR Corp. (Minnesota, USA). Statistical significance was calculated using the analysis of variance. A single 5 mg oral dose of bromocriptine decreased the mean prolactin concentration during the first 24 hours of treatment. Plasma VIP concentration was higher in prolactinoma patients compared to healthy subjects. There was no change in plasma VIP level after bromocriptine administration. CONCLUSIONS in patients with prolactin secreting adenoma the plasma VIP concentration is increased.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010911 Pituitary Neoplasms Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA. Pituitary Cancer,Cancer of Pituitary,Cancer of the Pituitary,Pituitary Adenoma,Pituitary Carcinoma,Pituitary Tumors,Adenoma, Pituitary,Adenomas, Pituitary,Cancer, Pituitary,Cancers, Pituitary,Carcinoma, Pituitary,Carcinomas, Pituitary,Neoplasm, Pituitary,Neoplasms, Pituitary,Pituitary Adenomas,Pituitary Cancers,Pituitary Carcinomas,Pituitary Neoplasm,Pituitary Tumor,Tumor, Pituitary,Tumors, Pituitary
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000704 Analysis of Variance A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable. ANOVA,Analysis, Variance,Variance Analysis,Analyses, Variance,Variance Analyses
D014660 Vasoactive Intestinal Peptide A highly basic, 28 amino acid neuropeptide released from intestinal mucosa. It has a wide range of biological actions affecting the cardiovascular, gastrointestinal, and respiratory systems and is neuroprotective. It binds special receptors (RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE). VIP (Vasoactive Intestinal Peptide),Vasoactive Intestinal Polypeptide,Vasointestinal Peptide,Intestinal Peptide, Vasoactive,Intestinal Polypeptide, Vasoactive,Peptide, Vasoactive Intestinal,Peptide, Vasointestinal,Polypeptide, Vasoactive Intestinal
D015175 Prolactinoma A pituitary adenoma which secretes PROLACTIN, leading to HYPERPROLACTINEMIA. Clinical manifestations include AMENORRHEA; GALACTORRHEA; IMPOTENCE; HEADACHE; visual disturbances; and CEREBROSPINAL FLUID RHINORRHEA. Adenoma, Prolactin-Secreting, Pituitary,PRL-Secreting Pituitary Adenoma,Pituitary Adenoma, Prolactin-Secreting,Lactotroph Adenoma,Macroprolactinoma,Microprolactinoma,Prolactin-Producing Pituitary Adenoma,Prolactin-Secreting Pituitary Adenoma,Prolactinoma, Familial,Adenoma, Lactotroph,Adenomas, Lactotroph,Lactotroph Adenomas,Macroprolactinomas,Microprolactinomas,PRL Secreting Pituitary Adenoma,PRL-Secreting Pituitary Adenomas,Pituitary Adenoma, PRL-Secreting,Pituitary Adenoma, Prolactin Secreting,Pituitary Adenoma, Prolactin-Producing,Pituitary Adenomas, PRL-Secreting,Pituitary Adenomas, Prolactin-Producing,Pituitary Adenomas, Prolactin-Secreting,Prolactin Producing Pituitary Adenoma,Prolactin Secreting Pituitary Adenoma,Prolactin-Producing Pituitary Adenomas,Prolactin-Secreting Pituitary Adenomas,Prolactinomas

Related Publications

A Makowska, and W Zgliczyński, and J Słowińska-Srzednicka, and P Soszyński, and S Zgliczyński
Increased plasma fibronectin concentration in diabetic patients with microalbuminuria.
January 1988, Diabetes care,
A Makowska, and W Zgliczyński, and J Słowińska-Srzednicka, and P Soszyński, and S Zgliczyński
[VIP removes the inhibition of prolactin secretion induced by dopamine in patients with prolactinoma].
January 1983, Comptes rendus des seances de l'Academie des sciences. Serie III, Sciences de la vie,
A Makowska, and W Zgliczyński, and J Słowińska-Srzednicka, and P Soszyński, and S Zgliczyński
Increased plasma concentration of adrenomedullin in patients with subarachnoid hemorrhage.
October 1998, Anesthesia and analgesia,
A Makowska, and W Zgliczyński, and J Słowińska-Srzednicka, and P Soszyński, and S Zgliczyński
Increased plasma homocysteine concentration in patients with chronic renal failure.
January 1992, Mineral and electrolyte metabolism,
A Makowska, and W Zgliczyński, and J Słowińska-Srzednicka, and P Soszyński, and S Zgliczyński
Significance of increased plasma adrenomedullin concentration in patients with cirrhosis.
May 1998, Journal of hepatology,
A Makowska, and W Zgliczyński, and J Słowińska-Srzednicka, and P Soszyński, and S Zgliczyński
Plasma VIP in patients with watery diarrhea syndrome.
April 1978, The American journal of digestive diseases,
A Makowska, and W Zgliczyński, and J Słowińska-Srzednicka, and P Soszyński, and S Zgliczyński
Increased plasma vaspin concentration in patients with sepsis: an exploratory examination.
January 2015, Biochemia medica,
A Makowska, and W Zgliczyński, and J Słowińska-Srzednicka, and P Soszyński, and S Zgliczyński
Increased D-dimer concentration in plasma of patients with severe acute urticaria.
December 2009, The British journal of dermatology,
A Makowska, and W Zgliczyński, and J Słowińska-Srzednicka, and P Soszyński, and S Zgliczyński
Hyperprolactinaemia associated with increased thyroid volume and autoimmune thyroiditis in patients with prolactinoma.
December 2013, Clinical endocrinology,
A Makowska, and W Zgliczyński, and J Słowińska-Srzednicka, and P Soszyński, and S Zgliczyński
Increased plasma concentration of matrix metalloproteinase-7 in patients with coronary artery disease.
August 2006, Clinical chemistry,
Copied contents to your clipboard!